- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06299514
RAFT-P&A Randomized Control Trial
Resynchronization for Ambulatory Heart Failure Trial in Patients With Chronic Atrial Fibrillation - Pharmacological Rate Control vs. Pace and Ablate With Bi-Ventricular or Conduction System Pacing
Atrial fibrillation (AF) is an irregular heartbeat that can cause symptoms of skipped beats, shortness of breath, stroke, or in some cases fluid in the lungs or legs. Treating AF is mostly to do with slowing the heart rate down so that the heart can get a chance to regain some energy. In some cases, slowing the heart rate is not easy to achieve as some elderly patients find it difficult to tolerate medications and suffer the side effects of such treatments. In those instances, there might be a possibility to permanently control the heart rate by implanting a pacemaker in the heart and intentionally damaging a regulatory region of the heart called the atrioventricular (AV) node. Damaging the AV node by a procedure called ablation results in the AF not being able to influence the bottom chambers (the ventricles) resulting in a slow rhythm. Therefore, if a pacemaker is implanted then the heart rate can be completely regulated by the pacemaker.
A complex pacemaker that stimulates both the right and left ventricles simultaneously (BiVP) has been used for the last decade prior to AV node ablation. More recently, a technique has been designed to reduce the number of leads in the heart, reduce procedure time and have a similar effect on the heart called Conduction System Pacing (CSP). However, this has not been directly compared to BiVP in a robust randomized control trial. There is also not enough existing evidence to show that a pace and ablate strategy is superior to optimal medical therapy. We intend to compare the efficacy of BiVP to CSP in patients who undergo AV node ablation for treating AF, in addition to comparing both pace and ablate methods to pharmacological therapy.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Habib R Khan, MBBS, PhD
- Phone Number: 519-6633746
- Email: habib.khan@lhsc.on.ca
Study Contact Backup
- Name: Abbie Pardo
- Email: abbie.pardo@lhsc.on.ca
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A5A5
- London Health Sciences Centre - University Hospital
-
London, Ontario, Canada, N6G5A5
- London Health Sciences Research
-
Contact:
- Abbie Pardo
- Phone Number: 86459 5196612111
- Email: abbie.pardo@lhsc.on.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- . Patients with permanent AF/persistent AF (in AF)
- . Patients with NYHA Class II -IVa HF symptoms
- . NT-proBNP ≥ 900 ng/L, or ≥ 600 ng/L if the patient has had a HF hospitalization within 1 year despite of guideline-driven medical therapy for HF of at least 3 months
- . any QRS duration for patients with LVEF >35%, QRS duration <150 ms for patients with LVEF ≤35%
Exclusion Criteria:
- In hospital patients needing intensive care or intravenous inotropic agent in the last 4 days
- patients with a life expectancy of ≤ 1 year from non-cardiac cause or anticipating a transplant within 1year
- acute coronary syndrome <4 weeks or coronary revascularization <3months
- unable or unwilling to provide informed consent
- uncorrected primary valvular disease or prosthetic tricuspid valve
- restrictive, hypertrophic, or reversible form of cardiomyopathy
- severe pulmonary diseases such as cor pulmonale or pulmonary hypertension (≥35mmHg)
- patients enrolled in competitive clinical trials that will affect the objectives of this study;
- existing CRT/BiVP or pacemaker
- resting heart rate ≥110 bpm on Holter monitoring
- patients who are pregnant or intend to become pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Pharmacological Therapy
Patients randomized to pharmacology rate control will receive guideline-directed HF management across all ranges of LVEF, including appropriate rate control medications.
ICD will be inserted in those patients who have LVEF ≤35%
|
Optimization of heart failure therapies includes maximum tolerated doses of beta-blockers, aldosterone antagonists, ACE inhibitors, ARB, diuretics, ARNis
Other Names:
|
Experimental: P&A-BiVP
Patients randomized to P&A-BiVP will receive a cardiac resynchronization therapy (CRT) pulse generator, and ICD if LVEF ≤35% within 10 working days of randomization.
Catheter AVNA will be performed within 4 weeks.
|
BiVentricular Pacing (BiVP) or Conduction System Pacing(CSP) followed by AtrioVentricular Node Ablation (AVNA)
Other Names:
|
Experimental: P&A-CSP
Patients randomized to P&A-CSP will receive a CSP and ICD if LVEF ≤35% within 10 working days of randomization.
Catheter AVNA will be performed within 4 weeks.
|
BiVentricular Pacing (BiVP) or Conduction System Pacing(CSP) followed by AtrioVentricular Node Ablation (AVNA)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Winratio
Time Frame: 12 months
|
Reduction in the hierarchical composite outcomes of all-cause mortality and HF events frequency, and improvement in QOL.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality
Time Frame: 12 months
|
Mortality from any cause within the 12 month of follow up period
|
12 months
|
Cardiovascular mortality
Time Frame: 12 months
|
Mortality attributed to cardiovascular causes within 12 month follow up period
|
12 months
|
Number of heart failure events
Time Frame: 12 months
|
Heart failure related presentations to health care facilities necessitating intravenous diuretics or overnight stay
|
12 months
|
All-cause hospitalization
Time Frame: 12 months
|
ER admission or overnight stay
|
12 months
|
Quality of Life -Kansas City Cardiomyopathy Questionairre (KCCQ)
Time Frame: 6 months
|
Change in Kansas HF score from baseline.
KCCQ is a 23-item self-administered questionnaire that measures the participant's perception of their health status, including their HF symptoms, impact on physical and social function and how their HF impacts the quality of life (QoL).
KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), QoL (3 items) and social limitations (4 items).
Scores were generated for each domain and scaled from 0 to 100, with 0 denoting the worst and 100 the best possible status.
|
6 months
|
Exercise
Time Frame: 6 months
|
change in 6 minute walk distance from baseline
|
6 months
|
Biochemical marker
Time Frame: 6 months
|
Change in NTproBNP from baseline
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4754
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on Medication
-
Joke WuytsAssociation of Belgian Pharmacies (APB)Completed
-
University of TennesseeKali Care; Barney's Pharmacy; Creative Care Pharmacy; Hutton Pharmacy; Mustang DrugTerminated
-
Diakonhjemmet HospitalUniversity of Oslo; Diakonhjemmet Hospital Pharmacy; Diakonhjemmet FoundationCompletedDrug-Related Side Effects and Adverse Reactions | Drug Interaction Potentiation | Medication Compliance | Remission | Medicinal Substance; Adverse EffectNorway
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); David Braley and Nancy Gordon... and other collaboratorsRecruitingPolypharmacy | Multi-morbidity | Medication Therapy ManagementCanada
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); David Braley and Nancy Gordon... and other collaboratorsRecruitingPolypharmacy | Multi-morbidity | Medication Therapy ManagementCanada
-
University of North Texas Health Science CenterUniversity of California, San Francisco; University of Minnesota; Walgreens,...Active, not recruitingHypertension | Diabetes Mellitus, Type 2 | HIV/AIDSUnited States
-
Aalborg University HospitalCompletedGraves Disease | Hyperthyroidism
-
Karl Landsteiner University of Health SciencesParacelsus Medical UniversityCompletedStroke | Dysphagia | Cerebral Infarction | Stroke, AcuteAustria
-
McMaster UniversityCanadian Frailty Network; Labarge Optimal AgingTerminatedFrailty | Polypharmacy | Long-term CareCanada
-
Universidad Miguel Hernandez de ElcheFundación Pública Andaluza Progreso y Salud; Servicio Aragonés de Salud (SALUD) and other collaboratorsNot yet recruitingCaregivers of Multi-pathological and Polypharmacy Adults